Alkermes (ALKS) Expected to Announce Earnings on Thursday

Alkermes (NASDAQ:ALKS) is expected to post its quarterly earnings results before the market opens on Thursday, February 20th. Analysts expect Alkermes to post earnings of $0.80 per share and revenue of $379.74 million for the quarter. Alkermes has set its FY 2025 guidance at 1.030-1.210 EPS.Parties interested in participating in the company’s conference call can do so using this link.

Alkermes (NASDAQ:ALKS) last issued its earnings results on Wednesday, February 12th. The company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.81 by $0.11. Alkermes had a net margin of 22.15% and a return on equity of 24.92%. On average, analysts expect Alkermes to post $2 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Alkermes Stock Up 0.1 %

Shares of Alkermes stock opened at $35.94 on Wednesday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.03 and a current ratio of 3.45. The stock has a market capitalization of $5.84 billion, a PE ratio of 18.43, a price-to-earnings-growth ratio of 1.83 and a beta of 0.49. Alkermes has a 52-week low of $22.90 and a 52-week high of $36.45. The company has a 50-day simple moving average of $30.49 and a two-hundred day simple moving average of $28.87.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. JPMorgan Chase & Co. decreased their price objective on shares of Alkermes from $32.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Stifel Nicolaus upgraded shares of Alkermes from a “hold” rating to a “buy” rating and boosted their target price for the company from $25.00 to $36.00 in a research report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft began coverage on shares of Alkermes in a research report on Tuesday, February 11th. They set a “buy” rating and a $40.00 target price for the company. HC Wainwright restated a “neutral” rating and set a $46.00 target price on shares of Alkermes in a research report on Thursday, February 13th. Finally, StockNews.com upgraded shares of Alkermes from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Alkermes has a consensus rating of “Moderate Buy” and an average price target of $37.25.

Insider Buying and Selling at Alkermes

In other news, EVP Craig C. Hopkinson sold 144,419 shares of Alkermes stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $35.53, for a total value of $5,131,207.07. Following the transaction, the executive vice president now owns 57,875 shares of the company’s stock, valued at $2,056,298.75. The trade was a 71.39 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Cato T. Laurencin sold 2,691 shares of Alkermes stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $31.85, for a total transaction of $85,708.35. Following the completion of the transaction, the director now directly owns 23,013 shares in the company, valued at approximately $732,964.05. The trade was a 10.47 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 323,608 shares of company stock valued at $10,854,725. Company insiders own 4.89% of the company’s stock.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.